Alterity Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

– ath434 improved motor performance and general function in a primate model of parkinson's disease – – ath434-201 phase 2 baseline data confirm approach to target biomarkers for slowing disease progression – – 12-month data from biomuse study shows key biomarker is associated with  disease progression in msa – melbourne, australia and san francisco, april 17, 2024 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters were presented at the american academy of neurology (aan) 2024 annual meeting taking place april 13-18, 2024, in denver, colorado, usa...

Melbourne, australia and san francisco, april 10, 2024 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data on ath434 will be presented at the world orphan drug congress usa 2024 taking place april 23-25, 2024 in boston, ma.

Melbourne, australia and san francisco, march 27, 2024 (globe newswire) -- alterity therapeutics limited (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a a$3.9 million cash refund from the australian taxation office under the australian government's research and development tax incentive (r&dti) scheme.

– positive efficacy data for ath434 in a primate model of parkinson's disease to be presented at international conference –

- ath434-201 trial on track to complete in november 2024 – - top-line data expected in january 2025 - melbourne, australia and san francisco, feb. 06, 2024 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent data monitoring committee (dmc) has completed its second review of trial data and recommended the ath434-201 phase 2 study continue as planned. the ath434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ath434 in patients with early-stage multiple system atrophy (msa), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23-25, 2024 in Boston, MA.

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease to be Presented at International Conference –

Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.

MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast on Wednesday, 6 December 2023 in Australia / Tuesday, 5 December 2023 in the United States. Details are listed below and registration is required.

Shares of Alterity Therapeutics (NASDAQ: ATHE ) — which specializes in neurodegenerative diseases and neurological disorders — are skyrocketing today. Undergirding sentiment on Monday is groundbreaking research regarding Parkinson's disease (PD) in primates.

Shares in Alterity Therapeutics soared after the biotech firm disclosed promising new clinical trial data for its Parkinson's disease treatment.

MELBOURNE, Australia and SAN FRANCISCO, June 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present a corporate overview and participate in a Q&A discussion at the MST Access Rare Diseases, Rich Returns Forum on Thursday, 22 June 2023 at 10:30 a.m. AEST (Wednesday, 21 June 2023 at 5:30 p.m. Pacific Time).

MELBOURNE, Australia and SAN FRANCISCO, May 19, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present at the SHARE Series Monday Management Update on Monday, May 22, 2023, at 11:00 am ET or 1:00am AEST Tuesday, May 23, 2023.

Alterity Therapeutics's ATHE data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease.  [ALERT[ Matt Maley just released his latest pick with an upside of over 100% in 2 years.

These penny stocks climbed during premarket trading, here's why The post Hot Penny Stocks to Watch Right Now That Are Moving in Premarket appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.